GlassScriptPhysician profile
Samuel John Chantilis
NPI 1386696052
$2,596.57
in general payments reported to CMS, 2019-2025
15 companies · $197 in 2025
The $197 reported for 2025 was more than what a typical Reproductive Endocrinology provider received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $743 · 2020: $324 · 2021: $379 · 2022: $579 · 2023: $139 · 2024: $235 · 2025: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $571.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $571.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $905.13 | 2019-2024 | Stripper |
| Organon LLC | $361.13 | 2021-2025 | Follistim Aq, Pregnyl, Ganirelix Acetate |
| Vitrolife INC. | $350.33 | 2022 | |
| Ferring Pharmaceuticals INC. | $247.82 | 2019-2025 | Menopur |
| Emd Serono, INC. | $172.04 | 2019-2025 | |
| Covidien LP | $150.58 | 2019 | |
| Merck Sharp & Dohme LLC | $104.50 | 2019-2021 | |
| Caldera Medical, INC | $89.60 | 2021 | |
| Abbvie INC. | $67.89 | 2019-2020 | |
| Meditrina | $58.16 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $24.69 | 2023 | Myfembree |
| Minerva Surgical, INC | $23.09 | 2021 | |
| Exeltis, USA INC. | $17.78 | 2020 | |
| Duchesnay USA Incorporated | $12.78 | 2019 | |
| Therapeuticsmd, INC. | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Chantilis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.